Prime Medicine, Inc. Prepaid Expense and Other Assets, Current
Prime Medicine, Inc. (PRME) had Prepaid Expense and Other Assets, Current of $19.21 million as of 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2023-11-03
- 2023-09-30: Prepaid Expense and Other Assets, Current $19.21M.
- 2023-06-30: Prepaid Expense and Other Assets, Current $10.87M.
- 2023-03-31: Prepaid Expense and Other Assets, Current $3.98M.
- 2022-12-31: Prepaid Expense and Other Assets, Current $2.70M.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2023-09-30 | $19.21M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $10.87M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $3.98M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.70M 10-Q · filed 2023-11-03 |
| 2022-09-30 | $2.18M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $959.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |